Abstract
Obesity has reached epidemic proportions worldwide and is now a major healthcare problem. Likewise, there are a number of cardiovascular risk factors and metabolic factors associated with obesity and this clustering contributes to the disease known as metabolic syndrome or syndrome X. Metabolic syndrome over a number of years can cause end organ damage resulting in morbidity and mortality. Metabolic syndrome and obesity are major contributing factors to the increase in nephropathy and end stage renal disease. Interestingly, an imbalance between cyclooxygenase-2 (COX-2) and cytochrome P450 (CYP450) enzymes in the kidney may contribute to the nephropathy associated with metabolic syndrome. Recent studies have demonstrated that COX-2 inhibition decreases renal cytokine levels and glomerular injury in obese rats. Therefore, COX-2 and CYP450 metabolites are therapeutic targets for the treatment of renal disease related to metabolic syndrome.
Keywords: Epoxyeicosatrienoic acids, endothelium-derived hyperpolarizing factor, kidney, obesity, CYP450 metabolites
Current Enzyme Inhibition
Title: Eicosanoid Inhibitors as Therapeutic Targets for Metabolic Syndrome Related Kidney Disease
Volume: 2 Issue: 1
Author(s): John D. Imig and Xueying Zhao
Affiliation:
Keywords: Epoxyeicosatrienoic acids, endothelium-derived hyperpolarizing factor, kidney, obesity, CYP450 metabolites
Abstract: Obesity has reached epidemic proportions worldwide and is now a major healthcare problem. Likewise, there are a number of cardiovascular risk factors and metabolic factors associated with obesity and this clustering contributes to the disease known as metabolic syndrome or syndrome X. Metabolic syndrome over a number of years can cause end organ damage resulting in morbidity and mortality. Metabolic syndrome and obesity are major contributing factors to the increase in nephropathy and end stage renal disease. Interestingly, an imbalance between cyclooxygenase-2 (COX-2) and cytochrome P450 (CYP450) enzymes in the kidney may contribute to the nephropathy associated with metabolic syndrome. Recent studies have demonstrated that COX-2 inhibition decreases renal cytokine levels and glomerular injury in obese rats. Therefore, COX-2 and CYP450 metabolites are therapeutic targets for the treatment of renal disease related to metabolic syndrome.
Export Options
About this article
Cite this article as:
Imig D. John and Zhao Xueying, Eicosanoid Inhibitors as Therapeutic Targets for Metabolic Syndrome Related Kidney Disease, Current Enzyme Inhibition 2006; 2 (1) . https://dx.doi.org/10.2174/157340806775473544
DOI https://dx.doi.org/10.2174/157340806775473544 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chelation Therapy for Metal Intoxication: Comments from a Thermodynamic Viewpoint
Mini-Reviews in Medicinal Chemistry Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy
Current Medicinal Chemistry Therapeutic Application of Melatonin in the Treatment of Melanoma: A Review
Current Cancer Therapy Reviews Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
Current Pharmaceutical Design The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness
Current Drug Targets Detrimental Effects of Hyperglycemia in Acute Coronary Syndromes: from Pathophysiological Mechanisms to Therapeutic Strategies
Mini-Reviews in Medicinal Chemistry Antidiabetic Agents in Patients with Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: Metabolism and Clinical Practice
Current Drug Metabolism Prorenin and the (Pro)renin Receptor in Retinal Pathology
Current Hypertension Reviews The Role of Transforming Growth Factor β1 in the Regulation of Blood Pressure
Current Hypertension Reviews Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease
Current Cardiology Reviews Pharmacotherapy Before and After Endovascular Repair of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology The Effects of Nanoencapsulated Curcumin-Fe3O4 on Proliferation and hTERT Gene Expression in Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Establishing Genomic/Transcriptomic Links Between Alzheimer’s Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach
CNS & Neurological Disorders - Drug Targets Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology RAAS Inhibition and Cardiorenal Syndrome
Current Hypertension Reviews Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry The Antidiabetic Therapeutic Potential of Dietary Polyphenols
Current Pharmaceutical Biotechnology T-cell Activation Induces Dynamic Changes in miRNA Expression Patterns in CD4 and CD8 T-cell Subsets
MicroRNA